Dronabinol
Product Images NDC 60687-386

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dronabinol (NDC 60687-386). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2.5 mg Dronabinol Capsule Blister 01.jpg

Label sheet containing multiple identical labels for DRONABINOL capsules USP 2.5 mg by American Health Packaging. Each label includes the drug name, strength, dosage form, a barcode, control number (NDC), expiration date placeholder, lot number placeholder, and the labeler's location in Columbus, Ohio.*

FDA Label Image

2.5 mg Dronabinol Capsules Carton 01.jpg

Packaged label for DRONABINOL capsules, USP with a strength of 2.5 mg. The label indicates a bottle containing 100 capsules (10 x 10), marked Rx Only. It includes handling instructions for pharmacists and storage conditions, and shows the labeler American Health Packaging located in Columbus, Ohio.*

FDA Label Image

5 mg Dronabinol Capsule Blister 01

Sheet of multiple rectangular labels for DRONABINOL Capsules, USP 5 mg by American Health Packaging. Each label includes the drug name, strength, dosage form, a barcode, expiration and lot number placeholders, and the labeler's location.*

FDA Label Image

5 mg Dronabinol Capsules Carton 01

Dronabinol Capsules USP 5 mg label from American Health Packaging. The label shows the product name, dosage strength of 5 mg, and package size of 30 capsules (3 x 10). It includes storage instructions, a controlled substance symbol (CIII), and pharmacy dispensing information. The label also features a barcode and manufacturer details from Columbus, Ohio.*

FDA Label Image

Figure

A line graph showing mean appetite change from baseline over 6 weeks comparing Dronabinol 2.5 mg BID to placebo. The vertical axis represents appetite change in mm VAS, and the horizontal axis shows time in weeks. The Dronabinol group shows a greater increase in appetite compared to placebo, with statistically significant differences at weeks 4 and 6 (p < 0.05).*

FDA Label Image

Rhd08680

DRONABINOL softgel imprinted with RP 868 in black ink on an orange oblong capsule shape. The image shows both front and back views of the softgel. The labeler is American Health Packaging.*

FDA Label Image

Rho08670

DRONABINOL oral tablet with imprint RP 867 on one side, light yellow, capsule-shaped. The tablet is unscored with no visible strength or manufacturer markings. Labeler is American Health Packaging.*

FDA Label Image

Structure

Chemical structure diagram of the active ingredient dronabinol. The diagram shows the molecular framework with labeled hydroxy and methyl groups and stereochemistry indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.